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Abstract
Background: Inflammation is a prominent feature in Alzheimer’s disease (AD). It has been proposed that aging has
an effect on the function of inflammation in the brain, thereby contributing to the development of age-related
diseases like AD. However, the age-dependent relationship between inflammation and clinical phenotype of AD
has never been investigated.
Methods: In this study we have analysed features of the neuroinflammatory response in clinically and
pathologically confirmed AD and control cases in relation to age (range 52-97 years). The mid-temporal cortex of
19 controls and 19 AD cases was assessed for the occurrence of microglia and astrocytes by
immunohistochemistry using antibodies directed against CD68 (KP1), HLA class II (CR3/43) and glial fibrillary acidic
protein (GFAP).
Results: By measuring the area density of immunoreactivity we found significantly more microglia and astrocytes
in AD cases younger than 80 years compared to older AD patients. In addition, the presence of KP1, CR3/43 and
GFAP decreases significantly with increasing age in AD.
Conclusion: Our data suggest that the association between neuroinflammation and AD is stronger in relatively
young patients than in the oldest patients. This age-dependent relationship between inflammation and clinical
phenotype of AD has implications for the interpretation of biomarkers and treatment of the disease.
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Background
Alzheimer’s disease (AD) is a chronic neurodegenerative
disease and is the most common cause of dementia. Two
hallmarks of the disease are senile plaques, which are
mainly composed of extracellular deposits of amyloid b
(Ab), and neurofibrillary tangles, which consist of intracel-
lular aggregates of aberrantly phosphorylated tau protein.
Senile plaques are associated with an inflammatory
response as shown by an increased presence of activated
complement proteins, cytokines, and activated microglia
and astrocytes [1]. It is suggested that this inflammatory
response, also referred to as neuroinflammation, plays a
prominent and early role in AD [2-4]. A role for inflam-
mation in AD has recently gained strong support from
genome-wide association studies that have identified genes
involved in inflammation that are associated with
increased risk of developing AD [5,6].
The inflammatory response in AD is a double-edged
sword. It is a self-defence reaction aimed at eliminating
injurious stimuli and restoring tissue integrity. However,
inflammation may become a harmful process when it
becomes chronic. Chronic activation of the inflammatory
response in AD produces pro-inflammatory cytokines,
prostaglandins and reactive oxygen species that exacerbate
Ab deposition and induce neuronal dysfunction [7].
Despite wide acceptance of the idea that inflammation
contributes to AD, it remains unclear at what stages of
AD inflammation is beneficial or detrimental [8].
Clinicopathological studies suggest that neuroinflamma-
tion, and in particular microglial activation, is an early
event in AD pathology. The volume of tissue occupied by
microglia, the brain resident macrophages, increases with
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cases [2]. The volume density of microglia is already
increased in early pathological stages of AD and in cogni-
tively normal subjects with frequent presence of plaques
and tangles [3,4]. Clinical studies using positron emission
tomography and the peripheral benzodiazepine ligand
PK11195 as a marker for activated microglia indicate that
activation of microglia occurs already in mild and early
forms of AD-type dementia and precedes cerebral atrophy
in AD [9,10]. These data indicate that neuroinflammation
is involved at an early stage of AD pathogenesis.
It has recently been proposed that aging has an effect on
the function of inflammation in the brain. Some studies
have suggested that aging facilitates an imbalance between
pro- and anti-inflammatory mechanisms resulting in a low
grade, chronic pro-inflammatory status, referred to as
inflammaging, while other studies have proposed that
microglia deteriorate during aging [11,12]. These studies
have suggested that the effect of aging on inflammation in
the brain contributes to the development of age-related
diseases like AD. However, the age-dependent relationship
between inflammation and clinical phenotype of AD has
never been investigated. In this study, we examined the
presence of microglia and astrocytes, as markers of neu-
roinflammation, in clinically and pathologically confirmed
AD and non-demented control cases in relation to age.
Our data suggest that the association between neuroin-
flammation and AD is much stronger in relatively young
patients as compared to the oldest patients.
Methods
Case selection
Post-mortem brain material was obtained from the Nether-
lands Brain Bank (Amsterdam, The Netherlands). All
donors or their next of kin provided written informed con-
sent for brain autopsy and use of tissue and medical
records for research purposes. Between 1999 and 2001
non-demented control and AD cases were sequentially
selected. Dementia status at death was determined on the
basis of all information available for each case during the
last year of life. Severity of dementia was measured using
the Global Deterioration Scale (GDS) [13]. Neuropatholo-
gical evaluation was performed on formalin fixed, paraffin
embedded tissue from different sites, including the frontal
cortex (F2), temporal pole cortex, parietal cortex (superior
and inferior lobule), occipital pole cortex and the hippo-
campus (essentially CA1 and entorhinal area of the para-
hippocampal gyrus). The distribution and the density of
neurofibrillary tangles was determined in Bodian-stained
sections, while senile plaques were stained with the methe-
namine silver method [14]. AD pathology was staged
according to Braak and Braak [15]. Cases with mixed
Parkinson’so rL e w yb o d yd i s e a s ew e r ee x c l u d e df r o m
the study. Demographic information, clinical status,
neuropathological staging and APOE genotype are shown
in Table 1.
Immunocytochemistry
For immunohistochemical staining, formalin fixed (4%, 24
h) paraffin embedded tissue from mid-temporal cortex
was used. Sections (5 μm thick) were mounted on super-
frost-plus tissue slides (Menzel-Gläser, Germany) and
deparaffinized. Subsequently, sections were immersed in
0.3% H2O2 in methanol for 30 min to quench endogenous
peroxidase activity, and treated in 10 mM pH 6.0 citrate
buffer heated by microwave during 10 min for antigen
retrieval. Normal serum and antibodies were dissolved in
phosphate-buffered saline (PBS) containing 1% (w/v)
bovine serum albumin (BSA, Boehringer Mannheim, Ger-
many). Sections were pre-incubated for 10 min with nor-
mal rabbit serum (DAKO, Glostrup, Denmark). Primary
antibodies were incubated for 1 hr at room temperature.
See Table 2 for antigen, dilution and source of primary
antibodies. After washing with PBS, slides were incubated
with biotin-conjugated rabbit anti-mouse antibody (rabbit
anti-mouse F(ab’)2, 1:500 dilution, DAKO) for 30 min.
Subsequently, slides were incubated with streptavidin-bio-
tin horseradish peroxidase complex (streptABComplex/
HRP, 1:200 dilution, DAKO) for 60 min. Color was devel-
oped using 3,3’-diaminobenzidine (0.1 mg/ml, 0.02%
H2O2, 3 min) as chromogen. Sections were mounted with
Entellan (Merck, Darmstadt, Germany).
Quantitative analyses
For each case an area between the top and the depth of a
gyrus was selected at random. Contiguous microscopic
fields from the pial surface to the boundary with white mat-
ter perpendicularly to the axis of a gyrus made up a col-
umn. At least three columns were assessed per individual
case. AT8-immunoreactive neurofibrillary tangles were
counted using a 40 × objective (0.16 mm
2). Ab- and AT8-
positive plaques were counted using a 10 × objective (0.64
mm
2). In order to measure the amount of immunoreactiv-
ity for KP1, CR3/43 and GFAP, the area density of immu-
noreactivity was measured [4]. Contiguous microscopic
fields arranged in columns were examined with a 10 ×
objective. Full color images were obtained using a Zeiss
light microscope equipped with a digital camera. The area
density was quantified using Image-Pro Plus analysis soft-
ware (Media Cybernetics, Silver Spring, MD). Using this
method the percentage of the area of interest that is immu-
noreactive for a specific antibody is measured. Assessments
for different antibodies were performed in adjacent sections
and blind to the pathological and clinical categorization.
Statistical analyses
The Kruskall-Wallis test was used to evaluate differ-
ences between groups followed by the Mann-Whitney U
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Page 2 of 8Table 1 Clinical status, demographic information, disease duration, neuropathological staging and APOE genotype of
control and AD cases used in this study.
Case Diagnosis Sex Age (years) Duration (years) GDS Braak Brain weight (grs) PMD (hours: minutes) APOE genotype
1 CTRL F 52 0 0 1268 6:50 3-3
2 CTRL M 53 0 0 1341 14:25 3-3
3 CTRL F 64 0 0 1169 8:35 4-2
4 CTRL M 70 0 0 1560 7:45 4-3
5 CTRL F 72 0 1 1296 6:45 4-3
6 CTRL M 73 0 0 1267 24:45 3-3
7 CTRL F 76 0 1 1212 4:50 3-2
8 CTRL F 77 0 2 1213 9:15 4-3
9 CTRL M 78 0 1 1467 5:35 4-3
10 CTRL F 78 0 1 1047 6:30 4-3
11 CTRL M 78 0 1 1332 6:55 3-3
12 CTRL M 79 0 1 1334 7:40 4-3
13 CTRL M 82 0 2 1468 13:35 3-3
14 CTRL F 82 0 1 1280 5:30 3-2
15 CTRL F 83 0 2 1102 7:45 3-3
16 CTRL F 85 0 3 1199 9:00 4-3
17 CTRL F 88 0 2 1152 5:40 3-3
18 CTRL F 92 0 1 1031 7:15 3-2
19 CTRL M 98 0 1 1203 8:40 3-3
20 AD F 65 16 7 6 1115 5:40 3-3
21 AD M 67 ? 6 5 1170 5:22 4-4
22 AD F 70 10 7 6 1020 4:30 3-3
23 AD F 76 12 7 6 1170 5:30 4-3
24 AD M 78 8 6 5 1298 7:45 4-4
25 AD F 80 ? 7 6 946 5:20 4-4
26 AD M 80 9 5 6 1240 4:20 4-3
27 AD F 82 7 7 5 1013 4:10 4-3
28 AD F 83 5 5 4 1288 5:20 4-3
29 AD F 83 3 6 5 1095 3:45 4-3
30 AD F 86 10 6 4 1158 4:45 4-3
31 AD F 87 2 7 3 976 3:55 4-2
32 AD F 89 2 5 3 1212 4:10 3-3
33 AD F 91 4 4 3 1161 9:35 4-3
34 AD F 91 7 5 4 1101 3:45 4-3
35 AD F 93 10 6 4 943 6:15 3-3
36 AD F 94 4 5 2 1050 3:15 3-3
37 AD F 94 7 6 2 987 6:35 3-3
38 AD F 97 7 7 3 1016 7:00 3-3
CTRL, control case; AD, Alzheimer’s disease patient; F, female; M, male; GDS, Global Deterioration Scale; gr, gram; PMD, post-mortem delay.
Table 2 Primary antibodies used in this study.
Antibody Species Antigen Dilution Source
KP1 mouse CD68 1:400 Dako, Glostrup, Denmark
CR3/43 mouse HLA-DP/DQ/DR 1:50 Dako, Glostrup, Denmark
GFAP (clone 6F2) mouse GFAP 1:10 Monosan, Uden, The Netherlands
AT8 mouse Tau pSer202 and pThr205 1:1000 Pierce, Rockford, IL, USA
Ab1-17 mouse Ab1-17 1:50 Dako, Glostrup, Denmark
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regression analysis was performed to model the relation
between age and different variables in controls and AD
cases. Beta coefficients of the relation between age and
different variables were compared between control and
AD cases. A p value < 0.05 was taken as significant.
Results
The relative occurrence of AD pathological hallmarks and
neuroinflammation was assessed in two age-groups. A
post-mortem age of 80 years was used as a cut-off as it
provided comparable group sizes. The number of Ab-
immunoreactive plaques and AT8-positive plaques and
tangles were determined in each case. For assessment of
KP1, CR3/43 and GFAP immunoreactivity, the area density
was determined and expressed as the percentage of area
positive for each specific marker (Figure 1). For all markers
there were significant differences between AD and control
cases in the group of 80 years and younger, as well in the
group older than 80 years. Except for CR3/43, no signifi-
cant difference between control and AD cases could be
observed in the group older than 80 years. Within the AD
group, significant differences in AT8-positive tangles, KP1
and GFAP were observed between AD cases older and
younger than 80 years. This data indicates that, in contrast
to Ab deposits and AT8 positive plaques, the occurrence
of tangles, microglia and astrocytes is lower in old AD
cases (> 80 years) compared to younger AD cases.
To study more directly the association between age of
death and the area density of KP1, CR3/43 and GFAP in
AD cases and controls, regression analysis was performed.
The occurrence of KP1, CR3/43 and GFAP rapidly
decreases with age in AD cases, in contrast to control cases
(Figure 2). For all markers the 95% confidence intervals of
control and AD cases start to overlap between post-mor-
tem ages of 85 and 90 years. A significant beta-coefficient
for regression over age was observed for KP1, CR3/43 and
GFAP in AD cases. Comparison of respective beta-coeffi-
cients for regression over age confirmed significant differ-
ences between AD and control cases for KP1, CR3/43 and
GFAP (Table 3). These data indicate that the occurrence of
microglia and astrocytes decreases over age in AD, in con-
trast to control cases, suggesting that the association
between neuroinflammation and AD is stronger in cases
with relatively young age.
Apolipoprotein E (apoE) has been shown to play a role
in the innate immune response, and inheritance of the
APOE4 allele is associated with increased risk of develop-
ing AD [16,17]. The APOE genotype is indicated in Table
1. In this study, the incidence of APOE4 in control cases
younger than 80 years is 29% compared to 7% in older
control cases. For AD cases, the incidence of APOE4 in
cases younger than 80 years is 57% compared to 29% in
older AD cases.
Discussion
In this study, we compared the age-dependent presence of
microglia and astrocytes, which is indicative of a neuroin-
flammatory response, in controls and AD cases. We show
that the association between neuroinflammation and AD
is stronger in relatively young AD cases compared to old
AD cases. The difference in occurrence of these neuroin-
flammatory markers between AD and control cases
decreases over age. Non-demented controls and AD cases
were selected from sequentially performed autopsies over
a period of two years. Inclusion criteria for controls
included no reported signs of cognitive impairment during
life. The presence of neurofibrillary tangles or neuritic pla-
ques after neuropathological examination was not used as
an exclusion criteria for controls (see Braak stage, Table
1). Inclusion criteria for AD cases were based on clinical
signs of AD-type dementia. Dementia status at death was
determined on the basis of all information available for
each case during the last year of life. Severity of dementia
was measured using the Global Deterioration Scale (GDS),
which encompasses activities of daily living, behaviour and
cognition, and is not affected by the educational level of
patients [13]. In using the above mentioned inclusion cri-
teria and sequential selection over a period of two years
we sought to avoid possible bias related to age and severity
of the underlying pathology that causes the disease.
Previous reports have indicated that activation or pre-
sence of microglia as well as the occurrence of gliosis
increases with normal aging [18-20]. In the present
study a significant beta-coefficient was observed in con-
trol cases for GFAP (Table 3), indicating an increased
occurrence of astrocytes with normal aging. Although
levels of microglia appear to increase slightly with aging
in controls, no significant changes were observed. Prob-
ably, the statistical power of the current study is too low
to observe a significant increase in microglia over age in
controls. Other explanations, like differences in detec-
tion technique and markers, cannot be excluded. The
previously observed increased occurrence of these mar-
kers for microglia and astrocytes with normal aging sug-
gests that these markers could be considered as markers
for senescence rather than for inflammation. This sug-
gests the rather controversial idea that the high expres-
sion levels of these markers in younger AD patients are
am a r k e ro f‘exacerbated glial senescence’ at relatively
young ages that could be involved in the pathogenesis
of AD. Another interpretation of this data could be that
successful aging, i.e. without dementia, is associated
with an increased presence and function of microglial
cells, due to the increasing demand on the neuro-sup-
portive and neuroprotective roles of microglia [21].
There are indications that microglia have a role in neur-
ite development and it is hypothesized that microglia
regulate synapse physiology [22]. The increase in
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Page 4 of 8Figure 1 Relative occurrence of pathological hallmarks and neuroinflammation in controls and AD cases. Data represent the occurrence
(Y axis in number per 2 mm
2)o fA b immunoreactive plaques, AT8 immunoreactive plaques and tangles, and the relative occurrence (Y axis in
percentage) of quantified KP1 (CD68), CR3/43 (HLA class II), and GFAP immunoreactivity in control (CTRL) and AD cases of 80 years and younger
(≤ 80) or older than 80 years (> 80). Data are shown as mean level ± S.E.M.. * indicates significant difference.
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response [23], which might become less effective with
increasing age in AD. The connection between microglia
and neuronal function is reflected in the significantly
higher number of neurofibrillary tangles in AD patients
younger than 80 years compared to older AD patients
(Figure 1).
The observed decrease in neuroinflammation in the AD
group could reflect a selective loss of glial cells with the
aging process. It has been observed that microglial cells in
aged human brain are dystrophic, showing morphological
features indicative of senescence and degeneration, such
as cytoplasmic processes [24]. Association of senescent
microglia with tau pathology in AD may be interpreted as
an indirect sign of the age-dependent failing of the neuro-
supportive and neuroprotective roles of microglia that
contribute to the neurodegenerative process in AD
[12,21,24]. Determination of microglia senescence requires
a more detailed qualitative morphological assessment. The
quantification method used in this study did not assess
microglial morphology, which is required for this phenoty-
pic characterization. In addition, the markers used in the
current study are those generally used for the detection of
microglia and are not indicative of microglial activation
state [25-28], thereby not reflecting the dual role of micro-
glia in the inflammatory response in AD [29,30]. Future
studies are needed to address activation state and phenoty-
pic morphology, as well as selective loss of glial cells in AD
in relation to aging.
Inheritance of APOE4, the gene that encodes apolipo-
protein E4, is a major risk factor for late onset AD. The
incidence of the APOE4 allele in the general population is
20-25%, whereas the incidence in patients with AD rises
to 50-65%. The presence of at least one APOE4 allele has
been associated with earlier age at onset [17]. The
hypothesised frequency distribution of the association
between age at onset and the presence of APOE4 would
therefore suggest that the occurrence of APOE4 decreases
Figure 2 Neuroinflammation in relation to age in controls and
AD cases. Data represent the relation between age (X axis, in years)
and quantified KP1 (CD68), CR3/43 (HLA class II), and GFAP
immunoreactivity (Y axis, in arbitrary units) for controls (open dots)
and AD patients (closed dots). Straight lines represent regression
lines, with corresponding 95% confidence intervals.
Table 3 Beta-coefficients of the regression of the age-
dependent scores for Ab deposits, AT8-positive neuritic
plaques, AT8-positive neurofibrillary tangles, KP1, CR3/43
and GFAP immunoreactivity for control and AD cases
Beta-coefficient (Standard Error)
Variable CTRL AD p-value
Ab deposits 5.411 (3.672) -2.611 (4.845) 0.193
AT8 NPs 0.069 (0.033)* 0.153 (0.831) 0.912
AT8 NFTs 0.180 (0.062)* -2.416 (2.247) 0.212
KP1 0.001 (0.001) -0.007 (0.003)* 0.006
CR3/43 0.009 (0.003) -0.042 (0.017)* 0.003
GFAP 0.044 (0.020)* -0.791 (0.173)* 0.000
NPs, neuritic plaques; NFTs, neurofibrillary tangles; CTRL, control case; AD,
Alzheimer’s disease cases. P-value indicates difference between regressions of
the AD and control groups. * indicates significant beta-coefficient.
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immunomodulatory protein that affects both innate and
adaptive immune responses. Microglia derived form tar-
geted replacement mice carrying two copies of the APOE4
allele show a pro-inflammatory phenotype compared to
microglia derived from mice carrying two copies of the
APOE3 allele [16]. In the present study the incidence of
APOE4 in AD cases of 80 years and younger was 57%,
while the incidence of APOE4 in AD cases older than 80
years was much lower, at 29% (Table 1). This decreased
frequency of APOE4 alleles could explain the difference in
occurrence of neuroinflammation between young and old
AD patients, and supports the hypothesis that a proinflam-
matory genetic profile contributes to an earlier onset of
AD.
Inflammation has been advanced as one of the underly-
ing mechanisms that drives AD pathology; however, clini-
cal trials with anti-inflammatory drugs have generated
inconclusive results [32]. The timing of anti-inflammatory
treatment is crucial since clinical studies have indicated
that inflammation occurs in early stages of AD, perhaps
even before exceeding the clinical detection threshold
[9,10]. Data from the current study would imply that age
itself could be an important factor for the response to
therapy since the occurrence of inflammation in AD
dementia decreases with increasing age of death. In addi-
tion, we show that the occurrence of microglia and astro-
cytes in AD and non-demented cases starts to overlap
between post-mortem ages of 80 and 90 years. This data is
in line with earlier studies which report considerable over-
lap in the severity of neurofibrillary tangle and neuritic
plaque pathology between older patients with AD demen-
tia and non-demented control cases [33,34]. The study of
Savva et al. implies that the diagnostic value of biomarkers
related to the underlying biological process leading to
accumulation of tangles or plaques is much more promi-
nent in the relatively young compared with the oldest
patients, and indicates that the pathological substrate that
causes dementia is heterogeneous and age-dependent [33].
The age-dependent relationship between the underlying
biology and clinical phenotype of AD has implications for
the interpretation of biomarkers and treatment of the dis-
ease. Data from the current study implicates the impor-
tance of considering age when interpreting the results of
studies on inflammatory biomarkers for AD.
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